The Combination of circEPSTI1 and MIF Offers Diagnostic Value for Endometrial Cancer
Zhili Cui,Liyuan Zhou,Xin An,Wenli Liu,Jingxia Li,Yueping Zhang,Wei Zhang
DOI: https://doi.org/10.2147/ijgm.s441861
IF: 2.145
2024-04-09
International Journal of General Medicine
Abstract:Zhili Cui, 1 Liyuan Zhou, 1 Xin An, 2 Wenli Liu, 1 Jingxia Li, 1 Yueping Zhang, 3 Wei Zhang 4 1 Department of Gynecology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, 056002, People's Republic of China; 2 Department of Pathology, Handan First Hospital, Handan, Hebei, 056000, People's Republic of China; 3 Shexian Maternal and Child Health Hospital, Shexian, Hebei, 056004, People's Republic of China; 4 Department of Gynecology, Handan Traditional Chinese Medicine Hospital, Handan, Hebei, 056001, People's Republic of China Correspondence: Zhili Cui, Department of Gynecology, Affiliated Hospital of Hebei University of Engineering, No. 81 Congtai Road, Congtai District, Handan, Hebei, 056002, People's Republic of China, Tel + 86-3103962266, Email Background: Circular RNAs (circRNAs) exhibit unique patterns of expression and high levels of stability in patient plasma samples such that they represent ideal non-invasive biomarkers that can be leveraged to detect a wide array of diseases including endometrial cancer (EC). This study was designed to identify circRNAs with potential diagnostic utility in serum samples from EC patients while also evaluating the utility of macrophage migration inhibitory factor (MIF) as a biomarker when screening for this form of cancer in the clinic. Methods: Levels of circEPSTI1 and MIF were assessed in the plasma of EC patients and healthy subjects (n=186 each) through qPCR and ELISAs. The diagnostic utility of these biomarkers was assessed with receiver operating characteristic curve (ROC) analyses. Results: Relative to healthy subjects, EC patient serum contained significantly elevated circEPSTI1 and MIF. An association was noted between circEPSTI1 expression in stages, histologic grade, and residual tumor. ROC curves confirmed that serum circEPSTI1 levels distinguished between controls and patients with EC with an Area of 0.835 and serum MIF levels distinguished between controls and patients with EC with an Area of 0.6646. When instead diagnosing patients based on the combination of MIF and circEPSTI1, the Area further rose to 0.8604. Conclusion: Assessing the combination of circEPSTI1 and MIF may be a viable approach to reliably diagnosing EC. Keywords: circEPSTI1, MIF, diagnostic biomarker, endometrial cancer Endometrial cancer (EC) is the third most prevalent malignancy among females worldwide, 1 yet no reliable approaches to detecting EC in its early stage currently exist for women at average risk who are free of any symptoms. 2 Under most established guidelines, initial detection strategies most commonly include endometrial biopsy or transvaginal ultrasonography, but both of these approaches are subject to limitations. Diagnostic curettage is also commonly employed when seeking to definitively identify this tumor type, but this procedure is inherently invasive and requires the scraping of tissue specimens without clear visibility such that missed diagnoses may occur, while also exposing patients to the potential for endometrial bleeding of varying severity levels. EC tumors can also invade the muscle layer, contributing to metastatic progression and adverse patient outcomes. 3 This procedure is also highly specialized such that it can only be conducted by experienced gynecologists. As such, validated biomarkers that can more reliably aid in the diagnosis of EC are urgently needed in order to improve the prognosis of this form of cancer. Circular RNAs (circRNAs) are a unique subset of transcripts that are extremely stable and resistant to degradation owing to their structural characteristics, defined by a closed covalent loop of RNA. 4–6 Particular circRNAs have increasingly been shown to regulate a wide array of cancers and other diseases through their ability to modulate biological processes such as differentiation, glycolytic metabolism, survival, proliferation, and migration. 7,8 These findings have spurred growing interest in the application of circRNAs as therapeutic targets or diagnostic biomarkers in a range of pathological contexts. 9,10 Widespread circRNA dysregulation has recently been reported in EC, with certain circRNAs serving as important regulators of disease-related processes. 11,12 Of note, circEPSTI1 can reportedly enhance certain oncogenic activities in cervical cancer, 13 oral squamous cell carcinoma, 14 ovarian cancer, 15 non-small cell lung cancer, 16 and breast cancer. 17 How circEPSTI1 functions in EC, however, remains poorly understood. One recent study also determined that macrophage migration inhibitory factor -Abstract Truncated-
medicine, general & internal